期刊文献+

Caspase抑制剂对体外氧糖剥夺损伤大鼠海马神经元的保护作用 被引量:1

Protective effects of Caspase inhibitor on in vitro hippocampal neurons of rats with oxygen glucose deprivation injury
原文传递
导出
摘要 目的 探讨Caspase抑制剂对体外氧糖剥夺损伤大鼠海马神经元的保护作用及机制. 方法 新生SD乳鼠海马神经元经体外原代培养7d后分为对照组、氧糖剥夺/复氧组、Caspase抑制剂苄氧羰基-缬氨酰-丙氨酰-门冬氨酰氟甲基酮(Z-VAD-FMK)组和二甲基亚砜(DMSO)组,其中氧糖剥夺/复氧组氧糖剥夺6h后复糖复氧,Z-VAD-FMK组在氧糖剥夺复氧过程中加入20 μmol/L Z-VAD-FMK,DMSO组在氧糖剥夺复氧过程中加入1‰药物溶媒DMSO.复氧复糖24 h后光镜及电镜下观察各组海马神经元的形态学变化,MTT比色法测定细胞存活率和培养液中乳酸脱氢酶(LDH)含量,Annexin V-FITC/PI双染后流式细胞仪检测神经元凋亡率,比色法测定神经元Caspase-3活性,Western blotting法分析Caspase-3活性蛋白表达. 结果 氧糖剥夺/复氧组细胞胞体肿胀,部分胞膜破裂,细胞完整性破坏,细胞核水肿,线粒体肿胀,嵴排列混乱;Z-VAD-FMK组细胞损伤较氧糖剥夺/复氧组减轻,大多数神经元形态完整,细胞内颗粒增多,细胞器肿胀减轻,线粒体嵴结构存在,分布较规则.与氧糖剥夺/复氧组比较,Z-VAD-FMK组海马神经元吸光度值(0.204±0.019 vs 0.303±0.018)及细胞存活率(0.481%±0.045%vs 0.704%±0.040%)明显增高,LDH含量[(406.500±21.286) U/L vs(326.000±20.278) U/L]明显降低,细胞凋亡率(49.700%±3.100%vs 29.820%±2.839%)明显降低,反应Caspase-3活性片段的吸光度值明显降低,Caspase-3活性蛋白表达(1.070±0.077 vs 0.785±0.058)明显下降,差异均有统计学意义(P<0.05). 结论 Caspase抑制剂可通过抑制Caspase-3蛋白活性,减轻海马神经元的体外氧糖剥夺损伤. Objective To explore the protective effects of Caspase inhibitor on in vitro hippocampal neurons of rats with oxygen glucose deprivation (OGD) injury.Methods The primary hippocampal neurons from newborn Sprague-Dawley rats were cultured for 7 days,and then,divided into control group,OGD/re-OG treatment group,Caspase inhibitor (Z-VAD-FMK) treatment group and DMSO treatment group; and OGD/re-OG was performed in the later three groups for OGD duration of 6 h.Through the experimental process,20 μmol/L Z-VAD-FMK was given to the Z-VAD-FMK treatment group,while 1‰ DMSO was added into culture medium in the DMSO group.The morphology of the neurons was observed 24 hours after re-OG under light microscopy and electron microscopy.MTT assay was used to determine the rate of survived cells and lactate dehydrogenase (LDH) content in culture medium.The neurons apoptosis rate was measured by using flow cytometry (Annexin V-FITC/PI).Caspase-3 activity of neurons was analyzed by colorimetry.The protein expression of Caspase-3 wasassessed by Western blotting.Results Cells in the OGD/re-OG treatment group showed swelled body,some having ruptured membrane,cell integrity being damaged,cell nucleus edema,mitochondrial swelling and cristae ordered chaos; cells in the Z-VAD-FMK treatment group showed decreased injury as compared with the OGD/re-OG treatment group,having cell integrity; as compared with the OGD/re-OG treatment group,Z-VAD-FMK treatment group had significantly higher absorbance value (0.204±0.019 vs.0.303±0.018) and cell survivalrate (0.481%±0.045%vs.0.704%±0.040%),obviously decreased lactate dehydrogenase (LDH) content ([406.500±21.286] U/L vs.[326.000±20.278] U/L),apoptosis rate (49.700%±3.100% vs.29.820%±2.839%),absorbance value of the Caspase-3 active area and Caspase-3 protein expression (1.070±0.077 vs.0.785±0.058),with statistically differences (P〈0.05).Conclusions Caspase inhibitor may protect rat hippocampal neurons from oxygen glucose deprivation injury by inhibiting Caspase-3 activity.
出处 《中华神经医学杂志》 CAS CSCD 北大核心 2014年第5期467-471,共5页 Chinese Journal of Neuromedicine
基金 国家自然科学基金(30801081) 广东省医学科研基金(A2009179) 佛山市医学类科技攻关项目(201308046)
关键词 CASPASE抑制剂 海马神经元 氧糖剥夺损伤 Caspase inhibitor Hippocampal neuron Oxygen glucose deprivation
  • 相关文献

参考文献13

  • 1Schneider A,Bottiger BW,Popp E.Cerebral resuscitation after cardiocirculatory arrest[J].Anesth Analg,2009,108(3):971-979.
  • 2Lee JM,Zipfel GJ,Choi DW.The changing landscape of ischaemic brain injury mechanisms[J].Nature,1999,399 (6738 Suppl):A7-14.
  • 3Yemisci M,Gürsoy-ozdemir Y,Caban S,et al.Transport of a caspase inhibitor across the blood-brain barrier by chitosan nanoparticles[J].Methods Enzymol,2012,508:253-269.
  • 4Teschendorf P,Vogel P,Wippel A,et al.The effect of intracerebroventricular application of the caspase-3 inhibitor zDEVD-FMK on neurological outcome and neuronal cell death after global cerebral ischaemia due to cardiac arrest in rats[J].Resuscitation,2008,78(1):85-91.
  • 5Li H,Colbourne F,Sun P,et al.Caspase inhibitors reduce neuronal injury after focal but not global cerebral ischemia in rats[J].Stroke,2000,31(1):176-182.
  • 6姜骏,符岳,方向韶,常建星,蒋龙元,黄子通.大鼠海马神经元体外氧糖剥夺/复氧模型的构建[J].中华急诊医学杂志,2010,19(5):497-501. 被引量:14
  • 7谭盛,陈健,郭阳,陈瑞清,李粲,陈镇洲.大鼠成年海马神经干细胞体外氧糖剥夺/复氧模型的建立[J].中华神经医学杂志,2011,10(12):1238-1242. 被引量:6
  • 8Hoesch RE,Koenig MA,Geocadin RG.Coma after global ischemic brain injury:pathophysiology and emerging therapies[J].Crit Care Clin,2008,24(1):25-44.
  • 9Bakshi A,Keck CA,Koshkin VS,et al.Caspase-mediated cell death predominates following engraftment of neural progenitor cells into traumatically injured rat brain[J].Brain Res,2005,1065 (1-2):8-19.
  • 10Nagata S.Apoptotic DNA fragmentation[J].Exp Cell Res,2000,256(1):12-18.

二级参考文献23

  • 1田映红,李树基,李晓文,高天明.大鼠海马神经细胞体外缺糖缺氧模型制备方法的改进[J].中国组织工程研究与临床康复,2007,11(15):2810-2813. 被引量:10
  • 2Padosch SA,B(o)ttiger BW.Neuronal apoptosis following cerebral ischaemia:pathophysiology and possible therapeutic implications[J].Curr Opin Anaesthesiol,2003,16(5):439-445.
  • 3Ren D,Miller JD.Primary cell culture of suprachiasmatic nucleus[J].Brain Res Bull,2003,61(5):547-553.
  • 4Grammatopoulos TN,Morris K,Bachar C,et al.Angiotensin Ⅱ attenuates chemical hypoxia-induced caspase-3 activation in primary cortical neuronal cultures[J].Brain Res Bull,2004,62(4):297-303.
  • 5Griffin S,Clark JB,Canevari L.Astrocyte-neurone communication following oxygen-glucose deprivation[J].J Neurochem,2005,95(4):1015-1022.
  • 6Zhang F,Wang S,Signore AP,et al.Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia[J].Stroke,2007,38(8):2329-2336.
  • 7Chen XQ,Liu S,Qin LY,et al.Selective regulation of 14-3-3 eta in primary culture of cerebral cortical neurons and astrocytes during de-velopment[J].J Neurosci Res,2005,79(l/2):114-118.
  • 8Culmsee C,Zhu C,Landshamer S,et al.Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia[J].J Neurosci,2005,25(44):10262-10272.
  • 9Scorziello A,Pellegrini C,Forte L,et al.Differential vulnerability of cortical and cerebellar neurons in primary culture to oxygen glucose deprivation followed by reoxygenation[J].J Neurosci Res,2001,63 (l):20-26.
  • 10Wang S,Xing Z,Vosler PS,et al.Cellular NAD replenishment confers marked neuroprotection against ischemic cell death:role of enhanced DNA repair[J].Stroke,2008,39(9):2587-2595.

共引文献18

同被引文献34

  • 1周杰,章翔,蒋晓帆,林国城,高大宽,章薇,宋蕾.白藜芦醇对大鼠脑创伤后TNF-α和IL-1β影响的实验研究[J].中华神经医学杂志,2006,5(2):162-164. 被引量:12
  • 2Rosonke S, Legome E. Head trauma[J]. J Emerg Med, 2006, 31(4): 421-425.
  • 3Popovich PG, Longbrake EE. Can the immtme system be harnessed to repair the CNS[J]. Nat Rev Neurosci, 2008, 9(6): 481-493.
  • 4Chawla A. Control of macrophage activation and function by PPARs[J]. Cir Res 2010, 106(10): 1559-1569.
  • 5Thai SC, Heinemann M, Luh C, et al. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-gamma-independent mechanisms[J]. J Neurotrauma, 2011, 28(6): 983-993.
  • 6Villapol S, Yaszemski A_K, Logan TT, et al. Candesartan, an angiotensin Ⅱ AT (1)-receptor blocker and PPAR-gamma agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice[J]. Neuropsychopharmacology, 2012, 37(13): 2817-2829.
  • 7Almad A, Lash AT, Wei P, et al. The PPAR alpha agonis gemfibrozil is an ineffective treatment for spinal cord injured mice [J]. Exp Neurol, 2011,232(2): 309-317.
  • 8Chen XR, Besson VC, Beziand T, et al. Combination therapy with fenoflbrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury[J]. J Pharmacol Exp Ther, 2008, 326(3): 966-974.
  • 9Shibata N, Kawaguchi-ZNiida M, Yamamoto T, et al. Effects of the PPARgamma activator pioglitazone on P38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis[J]. Neurophathology, 2008, 28(4): 387-398.
  • 10Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study[J]. Dement Geriatr Cogn Disord, 2010, 30(2): 131-146.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部